Ahn HH, Carrington C, Hu Y, et al. Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers. Sci Rep. 2021;11(1):9733. Published 2021 May 6. doi:10.1038/s41598-021-89124-4 (work enabled by the center).
Berry S, Giraldo NA, Green BF, et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science. 2021;372(6547):eaba2609. doi:10.1126/science.aba2609
Dykema AG, Zhang B, Woldemeskel BA, et al. Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. J Clin Invest. 2021;131(10):e146922. doi:10.1172/JCI146922
Est-Witte SE, Farris AL, Tzeng SY, et al. Non-viral gene delivery of HIF-1α promotes angiogenesis in human adipose-derived stem cells. Acta Biomater. 2020;113:279-288. doi:10.1016/j.actbio.2020.06.042
Green JJ. Immunoengineering has arrived. J Biomed Mater Res A. 2021;109(4):397-403. doi:10.1002/jbm.a.37041
Hou J, Yang R, Vuong I, Li F, Kong J, Mao HQ. Biomaterials strategies to balance inflammation and tenogenesis for tendon repair. Acta Biomater. 2021;130:1-16. doi:10.1016/j.actbio.2021.05.043 (work enabled by the center).
Howard GP, Bender NG, Khare P, et al. Immunopotentiation by lymph-node targeting of a malaria transmission-blocking nanovaccine. Front Immunol. 2021;12:729086. Published 2021 Aug 27. doi:10.3389/fimmu.2021.729086 (work enabled by the center).
Isser A, Livingston NK, Schneck JP. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials. 2021;268:120584. doi:10.1016/j.biomaterials.2020.120584
Karlsson J, Rhodes KR, Green JJ, Tzeng SY. Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities. Expert Opin Drug Deliv. 2020;17(10):1395-1410. doi:10.1080/17425247.2020.1796628
Karlsson J, Tzeng SY, Hemmati S, et al. Photocrosslinked bioreducible polymeric nanoparticles for enhanced systemic siRNA delivery as cancer therapy. Adv Funct Mater. 2021;31(17):2009768. doi:10.1002/adfm.202009768
Kim J, Vaughan HJ, Zamboni CG, Sunshine JC, Green JJ. High-throughput evaluation of polymeric nanoparticles for tissue-targeted gene expression using barcoded plasmid DNA. J Control Release. 2021;337:105-116. doi:10.1016/j.jconrel.2021.05.047
Leone RD, Powell JD. Fueling the Revolution: Targeting metabolism to enhance immunotherapy. Cancer Immunol Res. 2021;9(3):255-260. doi:10.1158/2326-6066.CIR-20-0791
Luly KM, Choi J, Rui Y, Green JJ, Jackson EM. Safety considerations for nanoparticle gene delivery in pediatric brain tumors. Nanomedicine (Lond). 2020;15(18):1805-1815. doi:10.2217/nnm-2020-0110
McCurdy SR, Radojcic V, Tsai HL, et al. Signatures of GVHD and relapse after post-transplant cyclophosphamide revealed by immune profiling and machine learning [published online ahead of print, 2021 Oct 17]. Blood. 2021;blood.2021013054.
Mo F, Yu Z, Li P, et al. An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature. 2021;597(7877):544-548. doi:10.1038/s41586-021-03861-0
Neshat SY, Tzeng SY, Green JJ. Gene delivery for immunoengineering. Curr Opin Biotechnol. 2020;66:1-10. doi:10.1016/j.copbio.2020.05.008
Rhodes KR, Isser A, Hickey JW, et al. Biodegradable cationic polymer blends for fabrication of enhanced artificial antigen presenting cells to treat melanoma. ACS Appl Mater Interfaces. 2021;13(7):7913-7923. doi:10.1021/acsami.0c19955
Rhodes KR, Meyer RA, Wang J, Tzeng SY, Green JJ. Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction. Acta Biomater. 2020;112:136-148. doi:10.1016/j.actbio.2020.06.004
Routkevitch D, Sudhakar D, Conge M, et al. Efficiency of cytosolic delivery with Poly(β-amino ester) nanoparticles is dependent on the effective pKa of the polymer. ACS Biomater Sci Eng. 2020;6(6):3411-3421. doi:10.1021/acsbiomaterials.0c00271
Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021;131(2):e143226. doi:10.1172/JCI143226
Thompson EA, Cascino K, Ordonez AA, et al. Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Rep. 2021;34(11):108863. doi:10.1016/j.celrep.2021.108863
Thompson EA, Powell JD. Inhibition of the adenosine pathway to potentiate cancer immunotherapy: Potential for combinatorial approaches. Annu Rev Med. 2021;72:331-348. doi:10.1146/annurev-med-060619-02315
Tzeng SY, Patel KK, Wilson DR, Meyer RA, Rhodes KR, Green JJ. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy. Proc Natl Acad Sci U S A. 2020;117(8):4043-4052. doi:10.1073/pnas.1916039117
Vaughan HJ, Zamboni CG, Radant NP, et al. Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Mol Ther Oncolytics. 2021;21:377-388. Published 2021 Apr 16. doi:10.1016/j.omto.2021.04.004
Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight. 2020 Apr 23;5(8). doi: 10.1172/jci.insight.135597.
Targeting Metabolism as a Platform for Inducing Allograft Tolerance in the Absence of Long-Term Immunosuppression. Front Immunol. 2020;11:572. doi: 10.3389/fimmu.2020.00572.
Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, Collins SL, Tam AJ, Blosser RL, Patel CH, Englert JM, Arwood ML, Wen J, Chan-Li Y, Tenora L, Majer P, Rais R, Slusher BS, Horton MR, Powell JD. Targeting glutamine metabolism enhances tumor specific immunity by modulating suppressive myeloid cells [published online ahead of print, 2020 Apr 23]. J Clin Invest. 2020;131859. doi:10.1172/JCI131859
Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells. Clin Cancer Res. 2020 Apr 2;. doi: 10.1158/1078-0432.CCR-19-3487.
Tzeng SY, Patel KK, Wilson DR, Meyer RA, Rhodes KR, Green JJ. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy. Proc Natl Acad Sci U S A. 2020 Feb 7;. doi: 10.1073/pnas.1916039117.
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019 Nov 22;366(6468):1013-1021. doi: 10.1126/science.aav2588. Epub 2019 Nov 7.
Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discov. 2019 Sep;18(9):669-688. doi: 10.1038/s41573-019-0032-5. Epub 2019 Jul 30. Review.